Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Osiris Therapeutics, Inc.    OSIR

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2016 12/02/2016 12/05/2016 12/06/2016 12/07/2016 Date
5.62(c) 5.68(c) 5.47(c) 5.35(c) 5.26 Last
239 981 154 147 267 390 158 071 88 307 Volume
-5.55% +1.07% -3.70% -2.19% -1.68% Change
More quotes
Financials ($)
More Financials
Company
Osiris Therapeutics, Inc. engages in stem cell research and development of pharmaceutical products.Its regenerative medicine targets dermal burns, pressure ulcers, venous leg, diabetic foot ulcers, and tissue and bone repair.The company was founded by Peter A. Friedli and James S. Burns on December... 
More about the company
Latest news on OSIRIS THERAPEUTICS, INC.
12/05 OSIRIS THERAPEUTICS : Provides Update Regarding NASDAQ Listing Matters
12/03 OSIRIS THERAPEUTICS : Provides Update Regarding NASDAQ Listing Matters
12/02 OSIRIS THERAPEUTICS,INC. (NASDAQ : OSIR) Files An 8-K Other Events
12/02 OSIRIS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (for..
12/02 Osiris Provides Update Regarding NASDAQ Listing Matters
11/22 Peer-reviewed Publication on the use of Grafix® in High-Risk Peripheral Arter..
11/22 OSIRIS THERAPEUTICS : Provides Update Regarding NASDAQ Listing Matters
11/21 OSIRIS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continue..
11/21 OSIRIS THERAPEUTICS,INC. (NASDAQ : OSIR) Files An 8-K Notice of Delisting or Fai..
11/21 Osiris Provides Update Regarding NASDAQ Listing Matters
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/10 OSIRIS THERAPEUTICS : Regenerative Technologies And Restated Financials
11/08 Midday Gainers / Losers
11/08 Osiris Therapeutics releases revised revenue numbers; shares up 22%
06/10 Osiris chief resigns for medical reasons
06/03 Mesoblast trading halt to stay in place until June 10, bad news expected
Advertisement
Chart OSIRIS THERAPEUTICS, INC.
Duration : Period :
Osiris Therapeutics, Inc. Technical Analysis Chart | OSIR | US68827R1086 | 4-Traders
Full-screen chart
Technical analysis trends OSIRIS THERAPEUTI...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David A. Dresner President & Chief Executive Officer
Peter A. Friedli Chairman
Frank D. Czworka Chief Operating Officer
Gregory I. Law Chief Financial Officer, Secretary & Treasurer
Alla Danilkovitch Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
OSIRIS THERAPEUTICS, I..-45.28%184
AMGEN, INC.-10.50%107 951
GILEAD SCIENCES, INC.-28.38%95 476
CELGENE CORPORATION-1.98%91 001
REGENERON PHARMACEUTIC..-32.04%38 913
ACTELION LTD45.20%21 783
More Results